Trial Profile
Effects of Roflumilast on pulmonary vascular resistance in patients with COPD and sleep apnea (Overlap Syndrome) with and without non-invasive ventilation. A Pilot Study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2016
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease; Sleep apnoea syndrome
- Focus Pharmacodynamics
- 02 Oct 2016 Status changed from recruiting to discontinued.
- 12 Oct 2012 New trial record